Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENACITY
CTR20260223Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tenecteplase in ischemic stroke, sponsored by Boehringer Ingelheim. Started Mar 2026; status: active.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20260223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260223.